» Authors » Carl Holvey

Carl Holvey

Explore the profile of Carl Holvey including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 29
Citations 175
Followers 0
Related Specialties
Top 10 Co-Authors
Published In
Affiliations
Soon will be listed here.
Recent Articles
1.
Datta I, Erridge S, Holvey C, Coomber R, Guru R, Holden W, et al.
Pain Pract . 2024 Nov; 25(1):e13438. PMID: 39545361
Introduction: Chronic pain (CP) affects 35.0%-51.3% of the UK population, with 67%-88% reporting sleep disturbances. Cannabis-based medicinal products (CBMPs) have shown therapeutic potential in managing CP. Evidence suggests poor sleep...
2.
Sridharan S, Erridge S, Holvey C, Coomber R, Holden W, Rucker J, et al.
J Pain Palliat Care Pharmacother . 2024 Oct; :1-14. PMID: 39417761
This cohort study aims to assess the outcomes of fibromyalgia patients enrolled in the UK Medical Cannabis Registry prescribed a homogenous selection of cannabis-based medicinal products (CBMPs). A cohort study...
3.
Francis A, Erridge S, Holvey C, Coomber R, Guru R, Darweish Medniuk A, et al.
Int Clin Psychopharmacol . 2024 Jul; PMID: 38976497
The aim of this study was to assess changes in validated patient-reported outcome measures after initiation of cannabis-based medicinal products (CBMPs) and the safety of CBMPs in patients with inflammatory...
4.
Murphy M, Kaur V, Bui H, Yang T, Erridge S, Holvey C, et al.
Mult Scler Relat Disord . 2024 May; 87:105665. PMID: 38728958
Introduction: Whilst disease-modifying therapies are the cornerstone for treatment of multiple sclerosis (MS), there is a need to develop novel therapeutics for the symptomatic sequalae of the disease. Cannabis-based medicinal...
5.
Francis A, Erridge S, Holvey C, Coomber R, Holden W, Rucker J, et al.
J Pain Palliat Care Pharmacother . 2024 Apr; 38(2):103-116. PMID: 38669060
Osteoarthritis accounts for 0.6% of disability-adjusted life years globally. There is a paucity of research focused on cannabis-based medicinal products (CBMPs) for osteoarthritic chronic pain management. This study aims to...
6.
Vivek K, Karagozlu Z, Erridge S, Holvey C, Coomber R, Rucker J, et al.
Brain Behav . 2024 Feb; 14(2):e3410. PMID: 38337193
Introduction: The primary aim of this study was to assess changes in sleep-specific health-related quality of life (HRQoL) for those prescribed cannabis-based medicinal products (CBMPs) for insomnia. Methods: A case...
7.
Li A, Erridge S, Holvey C, Coomber R, Barros D, Bhoskar U, et al.
Int Clin Psychopharmacol . 2024 Feb; 39(6):350-360. PMID: 38299624
This study aims to analyze changes in health-related quality of life (HRQoL) and safety in patients with generalized anxiety disorder (GAD) prescribed a homogenous selection of cannabis-based medicinal products (CBMPs)....
8.
Murphy M, Erridge S, Holvey C, Coomber R, Rucker J, Sodergren M
Neuropsychopharmacol Rep . 2023 Dec; 44(1):129-142. PMID: 38155535
Background: Research on cannabis-based medicinal products (CBMPs) in anxiety remains inconclusive due to a paucity of high-quality evidence. Studies indicate a bidirectional relationship between generalized anxiety disorder (GAD) and sleep...
9.
Ittiphakorn P, Erridge S, Holvey C, Coomber R, Rucker J, Sodergren M
Neuropsychopharmacol Rep . 2023 Dec; 43(4):596-606. PMID: 38058251
Aim: This study aims to analyze the health-related quality of life (HRQoL) and safety outcomes in attention-deficit/hyperactivity disorder (ADHD) patients treated with cannabis-based medicinal products (CBMPs). Methods: Patients were identified...
10.
Erridge S, Leung O, Holvey C, Coomber R, Beri S, Khan S, et al.
Neuropsychopharmacol Rep . 2023 Dec; 43(4):616-632. PMID: 38057993
Introduction: While there is increasing evidence of the effects of cannabis-based medicinal products (CBMPs) on health-related quality of life (HRQoL), a major limitation of the current literature is the heterogeneity...